You are here:

solifenacin and tamsulosin (Vesomni)

Advice

following an abbreviated submission

solifenacin succinate plus tamsulosin hydrochloride 6mg / 0.4mg modified release tablet (Vesomni®) is accepted for use within NHS Scotland.

Indication under review: for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.

In patients for whom concomitant use of solifenacin succinate and tamsulosin hydrochloride is appropriate, Vesomni® allows administration of a single tablet at a lower cost compared to the individual components administered separately.

Drug Details

Drug Name: solifenacin and tamsulosin (Vesomni)
SMC Drug ID: 945/14
Manufacturer: Astellas Pharma Ltd
Indication: For the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 March 2014

Back